On Tuesday Endo Pharmaceuticals (ENDP) announced that it is going to purchase Qualitest Pharmaceuticals, a privately owned generic firm of the US. The cost of the purchase is said to be one decimal two billion dollars.

Endo Pharmaceuticals Holdings Inc.'s reported its more than doubled fourth-quarter earnings, surpassing analysts' speculations, amid a $60 million accounting gain as the company posted that it witnessed a double-digit sales growth of both its branded and generic drugs.